Last updated: April 24, 2026
Who supplies desogestrel and ethinyl estradiol for pharma products?
What are the global API supplier groups for desogestrel (CAS 7439-84-5) and ethinyl estradiol (CAS 57-63-6)?
For manufacturers of combination oral contraceptives (COCs) and other steroid hormone products, supply chains typically split into two layers: API manufacturers (steroid production and purification) and API traders/distributors (secondary sourcing and logistics). The major supplier groups that show recurring commercial availability for both molecules are concentrated in Europe, India, China, and the US/EU specialty networks.
Below are the supplier categories and representative supplier companies that supply these APIs in commercial pharmaceutical supply.
Desogestrel API supply: which supplier types cover the market?
Desogestrel is a synthetic progestin. Market supply is dominated by steroid-capable API manufacturers and established pharma intermediates producers.
Common supplier types
- Steroid API manufacturers (full API production, purification, regulatory dossiers)
- Intermediates and hormone-specialty chemical producers (then convert or finalize API)
- API distributors and resellers (supply from multiple source sites)
Typical downstream use cases
- 3rd-generation progestin component in COCs
- Clinical and branded product supply continuity for women’s health portfolios
Ethinyl estradiol API supply: which supplier types cover the market?
Ethinyl estradiol is a synthetic estrogen. It is one of the most broadly produced estrogens in pharma, with supply from both large generics/API leaders and steroid-specialty manufacturers.
Common supplier types
- Large-scale steroid and hormone API manufacturers
- Specialty hormone API producers (niche capacity, smaller batch services)
- API distributors (multi-vendor contracting)
Typical downstream use cases
- Backbone estrogen component in COCs and related hormonal regimens
Which companies are active suppliers for desogestrel and ethinyl estradiol APIs?
API manufacturers (direct supply)
Representative active manufacturers and supply-channel participants for these APIs include:
| Company (group) |
Market role |
Typical relevance to these APIs |
| Hikma/Sanofi supply networks (EU distribution structures) |
Direct/controlled distribution |
Common in EU-based sourcing channels for hormonal APIs and tablets |
| Teva API and generics supply chains |
API manufacturing and/or reseller networks |
Strong historical footprint in women’s health lineups through generics networks |
| Cipla API network |
API and generics supply |
Typically supports estrogen/progestin combinations through its supply chain |
| Lupin |
API manufacturing and/or partner sourcing |
Known generics presence in hormonal products; often uses established API source sites |
| Mylan (now Viatris) supply networks |
Generics supply chains |
Broad API vendor base for COCs and hormonal products |
| Zydus |
API supply network |
Women’s health generics often rely on established steroid API sources |
| Aurobindo |
API supply network |
Strong in complex APIs and women’s health product lines |
| Dr. Reddy’s |
API supply network |
Uses steroid API vendor base for COCs and hormone products |
| Hetero Drugs |
API and formulations supply |
Steroid/hormone generics manufacturing ecosystem |
| Lannett (US) |
Drug products and sourcing ecosystem |
Supplies women’s health products in the US via API sourcing partners |
| Kopran / generic hormone ecosystem participants |
API/formulation sourcing |
Plays a role in supply of hormonal generics in key markets |
| Steroid-specialty manufacturers (global) |
Direct API manufacturing |
Many steroid APIs share production capability across estrogens and progestins |
Constraint: Exact “official” supplier qualification depends on product-specific regulatory dossiers (EDMF/DMF), site approvals, and current commercial status. Supplier lists vary by year and by country tender requirements.
API distributors and resellers (secondary supply)
The commercial market for these steroids also includes API distributors and resellers that provide multi-source purchasing and logistics. Common distributor models:
- Repackers and distributors with documented GDP chain
- Cross-border intermediaries for EU/US sourcing
- Contract importers serving hospitals, generics makers, and CMOs
Where these appear
- European contract manufacturing ecosystems
- US-based generics production (through approved vendor lists)
- Tender-driven purchases in LATAM, MENA, and EU secondary markets
How to validate the “right” supplier for desogestrel/ethinyl estradiol?
What evidence matters for regulated API procurement?
Procurement teams generally rely on:
- Regulatory filing linkage: DMF/EDMF status for the API and specific manufacturing site
- GMP manufacturing authorization: current GMP inspection and compliance history for the API site
- Quality documentation: CoA, impurity profile, polymorph/particle specs, residual solvents, and heavy metals
- Supply assurance: multi-year availability, lead times, and batch consistency
A practical supplier-screening pattern:
- Shortlist sites with documented DMF/EDMF access
- Confirm GMP site coverage in the target region
- Align spec limits with formulation requirements (tablet/coating, dissolution targets)
- Confirm impurity controls for steroid hormones (common sensitivity for hormonal APIs)
What specs typically get negotiated for these APIs?
Desogestrel API: typical technical acceptance points
While exact targets depend on dossier and region, desogestrel API qualification commonly includes:
- Identity: IR/UV/HPLC comparison to reference standard
- Assay: steroid content within pharmacopeial/dossier range
- Related substances: limits for process impurities and stereoisomers
- Residual solvents: compliant with ICH Q3C
- Water/volatile impurities: loss on drying or Karl Fischer limits
- Particle specs: when directly impacting milling/dosing uniformity
Ethinyl estradiol API: typical technical acceptance points
For ethinyl estradiol API:
- Identity and purity by chromatographic methods
- Assay and related substances within dossier thresholds
- Residual solvents and inorganic impurities compliance
- Polymorph and crystal form control when relevant to dissolution consistency
- Water content control
Which combination supply networks matter for desogestrel + ethinyl estradiol products?
Where do sourcing decisions concentrate in the value chain?
COCs typically consolidate procurement decisions around:
- A single API vendor for each component, or dual sourcing for continuity
- API packaging and transport that meet stability constraints
- Compatibility with tablet manufacturing specs (direct compression vs granulation)
Common consolidation patterns:
- EU generics and CMOs: prefer approved EU GMP API sites
- US generics: prefer vendor qualification with US inspection-ready documentation
- Tender markets: prioritize multiple vendor eligibility and price stability
Key Takeaways
- Desogestrel and ethinyl estradiol are widely sourced steroid APIs, with supply dominated by steroid-capable API manufacturers plus reseller/distributor networks.
- Supplier selection in regulated settings centers on site-level GMP authorization, regulatory dossier access (DMF/EDMF), and quality/spec alignment.
- Combination oral contraceptive supply chains typically dual-source each API component to protect continuity.
FAQs
1) Can one supplier provide both desogestrel and ethinyl estradiol?
Yes. Some steroid-capable manufacturers and contract networks supply both progestins and estrogens, though qualifications still require site-specific regulatory and GMP acceptance.
2) Do API suppliers differ by region (EU vs US vs LATAM)?
Yes. Procurement targets change based on inspection regimes, approved DMF/EDMF access, and local tender eligibility.
3) What is the fastest way to reduce API supply risk for these hormones?
Qualify at least two manufacturing sites per API component and maintain approval documentation for each site, aligned to the product dossier and specs.
4) What documentation do buyers usually require for steroid APIs?
CoA per batch, impurity/related substances profile, residual solvent compliance, identity and assay results, and reference standard traceability.
5) How do impurity profiles affect desogestrel and ethinyl estradiol sourcing?
Steroid APIs can have tight acceptance limits for related substances. Vendor qualification often depends on demonstrating impurity control consistent with the dossier and formulation stability needs.
References
[1] European Medicines Agency. European public assessment reports and chemical information for ethinyl estradiol and related steroid substances. EMA website.
[2] U.S. Food and Drug Administration. DMF and API quality guidance ecosystem references (quality and submission principles applicable to steroid APIs). FDA website.
[3] ICH. Q3C (Impurities: Residual Solvents). International Council for Harmonisation.
[4] ICH. Q3A/Q3B (Impurities in drug substances/products). International Council for Harmonisation.
